scholarly journals Tumor microenvironment triggered biodegradation of inorganic nanoparticles for enhanced tumor theranostics

RSC Advances ◽  
2020 ◽  
Vol 10 (45) ◽  
pp. 26742-26751
Author(s):  
Weitao Yang ◽  
Suhong Yang ◽  
Liping Jiang ◽  
Yujuan Zhou ◽  
Cuiling Yang ◽  
...  
Keyword(s):  
Tumor Microenvironment ◽  
Signal Amplification ◽  
Tumor Therapy ◽  
Inorganic Nanoparticles ◽  
Recent Advances ◽  
Tumor Theranostics

In this review, we summarize the recent advances in tumor microenvironment (TME)-triggered biodegradation of inorganic NPs accompanied by imaging signal amplification and the released ions-mediated tumor therapy.

Photoactive conjugated polymer/graphdiyne nanocatalyst for CO2 reduce into CO in living cells for hypoxia tumor treatment

2021 ◽  
Author(s):  
Endong Zhang ◽  
Zicheng Zuo ◽  
Wen Yu ◽  
Hao Zhao ◽  
Shengpeng Xia ◽  
...  
Keyword(s):  
Carbon Monoxide ◽  
Photodynamic Therapy ◽  
Tumor Microenvironment ◽  
Conjugated Polymer ◽  
Tumor Therapy ◽  
Living Cells ◽  
Tumor Treatment ◽  
Treatment Efficiency ◽  
Therapy Strategy ◽  
Co Gas

Carbon monoxide (CO) gas therapy has grown to be an emerging tumor therapy strategy to avoid low treatment efficiency of photodynamic therapy (PDT) caused by the hypoxia tumor microenvironment. However,...

Recent advances in the role of Th17/Treg cells in tumor immunity and tumor therapy

2021 ◽  
Author(s):  
Yin Qianmei ◽  
Su Zehong ◽  
Wang Guang ◽  
Li Hui ◽  
Gaojian Lian
Keyword(s):  
Tumor Immunity ◽  
Tumor Therapy ◽  
Treg Cells ◽  
Recent Advances

scholarly journals Macrophages/Microglia in the Glioblastoma Tumor Microenvironment

2021 ◽  
Vol 22 (11) ◽  
pp. 5775
Author(s):  
Jun Ma ◽  
Clark C. Chen ◽  
Ming Li
Keyword(s):  
Tumor Microenvironment ◽  
Myeloid Cells ◽  
Complex Interaction ◽  
Key Factors ◽  
Cell Markers ◽  
Tumor Associated Macrophage ◽  
Recent Advances ◽  
Definition Of

The complex interaction between glioblastoma and its microenvironment has been recognized for decades. Among various immune profiles, the major population is tumor-associated macrophage, with microglia as its localized homolog. The present definition of such myeloid cells is based on a series of cell markers. These good sentinel cells experience significant changes, facilitating glioblastoma development and protecting it from therapeutic treatments. Huge, complicated mechanisms are involved during the overall processes. A lot of effort has been dedicated to crack the mysterious codes in macrophage/microglia recruiting, activating, reprogramming, and functioning. We have made our path. With more and more key factors identified, a lot of new therapeutic methods could be explored to break the ominous loop, to enhance tumor sensitivity to treatments, and to improve the prognosis of glioblastoma patients. However, it might be a synergistic system rather than a series of clear, stepwise events. There are still significant challenges before the light of truth can shine onto the field. Here, we summarize recent advances in this field, reviewing the path we have been on and where we are now.

Recent advances in microneedles for tumor therapy and diagnosis

2021 ◽  
Vol 23 ◽  
pp. 101036
Author(s):  
Shiyang Lin ◽  
Yi Cao ◽  
Jiajie Chen ◽  
Zhengfang Tian ◽  
Yufang Zhu
Keyword(s):  
Tumor Therapy ◽  
Recent Advances ◽  
Therapy And Diagnosis

Recent Advances in Brain Tumor Therapy: Local Intracerebral Drug Delivery by Polymers

2004 ◽  
Vol 22 (1) ◽  
pp. 27-37 ◽  
Author(s):  
Christopher Guerin ◽  
Alessandro Olivi ◽  
Jon D. Weingart ◽  
H. Christopher Lawson ◽  
Henry Brem
Keyword(s):  
Drug Delivery ◽  
Brain Tumor ◽  
Tumor Therapy ◽  
Recent Advances ◽  
Brain Tumor Therapy

TAMI-31. GLIOBLASTOMA GENETIC DRIVERS DICTATE THE FUNCTION OF TUMOR-ASSOCIATED MACROPHAGES/MICROGLIA AND RESPONSES TO CSF1R INHIBITION

2021 ◽  
Vol 23 (Supplement_6) ◽  
pp. vi204-vi204
Author(s):  
Rohit Rao ◽  
Rong Han ◽  
Sean Ogurek ◽  
Lai Man Wu ◽  
Liguo Zhang ◽  
...  
Keyword(s):  
Tumor Microenvironment ◽  
Single Cell ◽  
Tumor Therapy ◽  
Tumor Associated Macrophages ◽  
Transcriptomic Profiling ◽  
Angiogenic Therapy ◽  
Landscape Characterization ◽  
Specific Tumor ◽  
Glioma Growth ◽  
Human Gbm

Abstract Tumor-associated macrophages/microglia (TAMs) are prominent microenvironment components in human glioblastoma (GBM) that are potential targets for anti-tumor therapy. However, TAM depletion by CSF1R inhibition showed mixed results in clinical trials. We hypothesized that GBM subtype-specific tumor microenvironment convey distinct sensitivities to TAM targeting. We generated syngeneic PDGFB-driven and RAS-driven GBM models that resemble proneural-like and mesenchymal-like gliomas, and determined the effect of TAM targeting by CSF1R inhibitor PLX3397 on glioma growth and progression. We also investigated the co-targeting of TAMs and angiogenesis on PLX3397-resistant RAS-driven GBM. Using single-cell transcriptomic profiling, we further explored differences in tumor microenvironment compositions and functions between the proneural-like and mesenchymal-like glioma models. We found that the growth of PDGFB-driven tumors was markedly inhibited by PLX3397. In contrast, depletion of TAMs at the early phase accelerated RAS-driven tumor growth and had no effects on other proneural and mesenchymal human GBM models. In addition, PLX3397-resistant RAS-driven tumors did not respond to PI3K signaling inhibition. Single-cell transcriptomic profiling revealed that PDGFB-driven gliomas induced expansion and activation of pro-tumor microglia, whereas mesenchymal RAS-driven gliomas elicited TAMs enriched in pro-inflammatory and angiogenic signaling. Co-targeting of TAMs and angiogenesis decreased cell proliferation and tumor mass in RAS-driven gliomas. Our work identifies functionally distinct TAM subpopulations in the growth of different glioma subtypes. Notably, we uncover a potential responsiveness of resistant mesenchymal-like gliomas to combined anti-angiogenic therapy and CSF1R inhibition. These data highlight the importance of microenvironment landscape characterization to optimally stratify glioma patients for TAM-targeted therapy.

Recent Advances in the Liquid-Phase Syntheses of Inorganic Nanoparticles

2004 ◽  
Vol 104 (9) ◽  
pp. 3893-3946 ◽  
Author(s):  
Brian L. Cushing ◽  
Vladimir L. Kolesnichenko ◽  
Charles J. O'Connor
Keyword(s):  
Liquid Phase ◽  
Inorganic Nanoparticles ◽  
Recent Advances

Recent Advances of Red/Near Infrared Light Responsive Carbon Dots for Tumor Therapy

2021 ◽  
Vol 42 (08) ◽  
pp. 1155-1171
Author(s):  
Fu-chun NAN ◽  
◽  
Xiao-kuang XUE ◽  
Jie-chao GE ◽  
Peng-fei WANG ◽  
...  
Keyword(s):  
Carbon Dots ◽  
Near Infrared ◽  
Tumor Therapy ◽  
Infrared Light ◽  
Near Infrared Light ◽  
Recent Advances

Glioblastoma Genetic Drivers Dictate the Function of Tumor-Associated Macrophages/Microglia and Responses to CSF1R Inhibition

2021 ◽  
Author(s):  
Rohit Rao ◽  
Rong Han ◽  
Sean Ogurek ◽  
Chengbin Xue ◽  
Lai Man Wu ◽  
...  
Keyword(s):  
Tumor Microenvironment ◽  
Single Cell ◽  
Tumor Therapy ◽  
Pi3k Signaling ◽  
Tumor Associated Macrophages ◽  
Transcriptomic Profiling ◽  
Angiogenic Therapy ◽  
Specific Tumor ◽  
Glioma Growth

Abstract Background Tumor-associated macrophages/microglia (TAMs) are prominent microenvironment components in human glioblastoma (GBM) that are potential targets for anti-tumor therapy. However, TAM depletion by CSF1R inhibition showed mixed results in clinical trials. We hypothesized that GBM subtype-specific tumor microenvironment convey distinct sensitivities to TAM targeting. Methods We generated syngeneic PDGFB-driven and RAS-driven GBM models that resemble proneural-like and mesenchymal-like gliomas, and determined the effect of TAM targeting by CSF1R inhibitor PLX3397 on glioma growth. We also investigated the co-targeting of TAMs and angiogenesis on PLX3397-resistant RAS-driven GBM. Using single-cell transcriptomic profiling, we further explored differences in tumor microenvironment cellular compositions and functions in PDGFB- and RAS-driven gliomas. Results We found that growth of PDGFB-driven tumors was markedly inhibited by PLX3397. In contrast, depletion of TAMs at the early phase accelerated RAS-driven tumor growth and had no effects on other proneural and mesenchymal GBM models. In addition, PLX3397-resistant RAS-driven tumors did not respond to PI3K signaling inhibition. Single-cell transcriptomic profiling revealed that PDGFB-driven gliomas induced expansion and activation of pro-tumor microglia, whereas TAMs in mesenchymal RAS-driven GBM were enriched in pro-inflammatory and angiogenic signaling. Co-targeting of TAMs and angiogenesis decreased cell proliferation and changed the morphology of RAS-driven gliomas. Conclusions Our work identify functionally distinct TAM subpopulations in the growth of different glioma subtypes. Notably, we uncover a potential responsiveness of resistant mesenchymal-like gliomas to combined anti-angiogenic therapy and CSF1R inhibition. These data highlight the importance of characterization of the microenvironment landscape in order to optimally stratify patients for TAM-targeted therapy.

scholarly journals Nanomaterials for molecular signal amplification in electrochemical nucleic acid biosensing: recent advances and future prospects for point-of-care diagnostics

2020 ◽  
Vol 5 (1) ◽  
pp. 49-66 ◽  
Author(s):  
Léonard Bezinge ◽  
Akkapol Suea-Ngam ◽  
Andrew J. deMello ◽  
Chih-Jen Shih
Keyword(s):  
Nucleic Acid ◽  
Molecular Diagnostics ◽  
Signal Amplification ◽  
Point Of Care ◽  
Future Prospects ◽  
Electrochemical Biosensing ◽  
Recent Advances ◽  
Point Of Care Diagnostics ◽  
Molecular Signal

This account reviews the major amplification strategies utilizing nanomaterials in electrochemical biosensing for robust and sensitive molecular diagnostics.

Sign in / Sign up

Export Citation Format

Share Document